Manifestation of renal disease in obesity: Pathophysiology of obesity-related dysfunction of the kidney

International Journal of Nephrology and Renovascular Disease

Volumn 2, Issue , 2009, Pages 39-49

  D'Elia, John A ^a   Roshan, Bijan ^a   Maski, Manish ^a   Weinrauch, Larry A ^a  

^a MOUNT AUBURN HOSPITAL   (United States)

Author keywords

Adiponectin; Albuminuria; Glomerulomegaly; Insulin; Leptin; Obesity; Podocyte hypertrophy

Indexed keywords

ADIPONECTIN; FATTY ACID; INSULIN; LEPTIN; NEPHRIN; PODOCIN; RESISTIN;

ADIPOSE TISSUE CELL; ADRENERGIC STIMULATION; ALBUMINURIA; BLOOD PRESSURE REGULATION; BODY WEIGHT; CREATININE CLEARANCE; DISEASE ASSOCIATION; FOCAL GLOMERULOSCLEROSIS; HUMAN; HYPERRENINEMIA; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY HYPERTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL ASSESSMENT; OBESITY; OBESITY RELATED KIDNEY DYSFUNCTION; PATHOPHYSIOLOGY; PHOSPHATE BALANCE; PODOCYTE; PROTEIN BINDING; PROTEIN SECRETION; RENOVASCULAR HYPERTENSION; REVIEW; SLEEP APNEA SYNDROME; WHITE ADIPOSE TISSUE;

EID: 77953458310     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Fox C, Larson M, Leip E, Culleton B, Wilson P, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844-850.
2. Timpson N, Harbord R, Smith G, Zacho J, Tybjaerg-Hansen A, Nordestgaard B. Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FTO/MC4R genotype. Hypertension. 2009;54:84-90.
3. Rheaume C, Arsenaylt, Belanger S, et al. Low cardiorespiratory fitness levels and elevated blood pressure. What is the contribution of visceral adiposity? Hypertension. 2009;54:91-97.
4. Tavakol M, Vincenti F, Assadi H, et al. Long-term renal function and cardiovascular disease risk in obese kidney donors. Clinical J of the American Society of Nephrology. 2009;4:1230-1238.
5. Obermayr R, Temml C, Gutjahr G, et al. Body mass index modifies the risk of cardiovascular death in proteinuric chronic kidney disease. Nephrology Dialysis and Transplantation. 2009;24:2421-2428.
6. Serra A, Romero R, Lopez D, et al. Renal injury in extremely obese patients with normal renal function. Kidney International. 2008;73:947-955.
7. Kato S, Nazneen A, Nakashima Y, et al. Pathological influence of obesity on renal structural changes in chronic kidney disease. Clinical Experimental Nephrology. 2009;9:169-173.
8. Goumenos D, Kawar B, El Nahas M, et al. Early histological changes in the kidney of people with morbid obesity. Nephrology Dialysis and Transplantation. 2009 July 13, [Epub ahead of print].
9. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004;291:2013.
10. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. NEJM. 2000;342:1378.
11. Chaudhary BA, Sklar AH, Chaudhary TK, Kolbeck RC, Speir Jr WA. Sleep apnea, proteinuria, and nephrotic syndrome. Sleep. 1988;11:69-74.
12. Sklar A, Chaudhary B. Reversible proteinuria in obstructive sleep apnea syndrome. Archives of Internal Medicine. 1988;148:87-89.
13. Sklar AH, Chaudhary BA, Harp R. Nocturnal urinary protein excretion rates in patients with sleep apnea. Nephron. 1989;51:35-38.
14. Tsioufis C, Thomopoulos C, Dimitriadis K, et al. Association of obstructive sleep apnea with urinary albumin excretion in essential hypertension: a cross-sectional study. Am J Kidney Dis. 2008;52:285-293.
15. Kambham N, Markowitz G, Valeri A, Lin J, D'Agati V. Obesityrelated glomerulopathy: an emerging epidemic. Kidney International. 2001;59:1498-1509.
16. Verani R. Obesity-associated focal segmental glomerulosclerosis: pathologic features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Diseases. 1992;20:629-634.
17. Bonnett F, Deprele C, Sassolas A, et al. Excessive body weight as a new risk factor for clinical and pathological progression in primary IgA nephritis. American J of Kidney Disease. 2001;37:1-12.
18. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF kappa B signaling through a cyclic AMP-dependent pathway. Circulation. 2000;102:1296-1301.
19. Stilmant M. Crescenteric glomerulonephritis. Chapter 3, page 40 in Pathology of Glomerular Disease, Editor Seymour Rosen. Churchill-Livingston, New York, 1983.
20. Hall J Mechanisms of abnormal renal sodium handling in obesity. Hypertension. Amer J Hypertension. 1997;10:49S-55S.
21. Haynes W, Sivitz W, Morgan D, Walsh S, Mark A. Sympathetic and cardiorenal actions of leptin. Hypertension. 1997;30:619-631.
22. Rossi GP, Belfiore A, Bernini G, et al; Primary Aldosteronism Prevalence in hYpertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertension patients. J Clin Endocrinol Metab. 2008;93:2566-2571.
23. Bentley-Lewis R, Adler GK, Perlstein T, Selly EW, Hopkins PN. Body mass index predicts aldosterone production in normotensive adults on a high salt diet. J Clin Endocrinol Metab. 2007;92:4472-4475.
24. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Amer J Physiology Renal Physiology. 2000;278:F817-F822.
25. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension. 1995;26:610-615.
26. Baron A. Hemodynamic actions of insulin. The American Journal of Physiology. 1994;267: Endocrinology Metabolism 30:E187-E202.
27. Liao J, Richards R, Zhang R, Reisin E. Effects of a modified low calorie diet in metabolic changes and kidney histology in young obese Zucker rats. J Am Soc Nephrology. 2007;18:823A.
28. Morales E, Valero M, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis. 2003;41:319-327.
29. Chagnac A, Weinstein T, Herman N, Hirsch J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrology. 2003;14:1480-1486.
30. Sasaki, Asanum H, Fujita M, et al. Metformin prevents progression of heart failure in dogs. Role of AMP-activated protein kinase. Circulation. 2009;119:2568-2577.
31. Coward RJM, Welsh GI, Kopziell A, et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes. 2007;56:1127-1135.
32. Sharma K, RamachandraRao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645-1656.
33. Bagby S. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic renal disease? J of the American Society of Nephrology. 2004;15:2775-2791.
34. Kim J, Wi J, Youn J. Plasma free fatty acids decrease insulin-stimulated skeletal muscle glucose uptake by suppressing glycolysis in conscious rats. Diabetes. 1996;45:446-453.
35. Hitomi H, Kiyomoto H, Nishiyama A, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007;50:750-755.
36. Callera G, Touyz R, Tostes R, et al. Aldosterone activates vascular p38MAP kinase and NADP oxidase via c-Src. Hypertension. 2005;45:773-779.
37. Coughlan MT, Thorburn DR, Penfold SA, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol. 2009 Apr;20(4):742-752.
38. Wendt T, Tanji N, Guo J, et al. Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy. J American Society of Nephrology. 2003;14:1383-1395.
39. Geltman J, Sun J, Keenan H, et al. Unexpected high prevalence of cardiovascular complications in type 1 diabetes of extreme duration. Diabetes. 2009;58:(S1)A199.
40. Roest P, Molin D, Schralkwijk C, et al. Specific local cardiovascular changes of N (carboxymethyl) lysine, vascular endothelial growth factor and Smad2 in the developing embryos coincide with maternal diabetes-induced congenital heart defects. Diabetes. 2009;58:1222-1228.
41. Schmidt AM, Yan S, Wautier J, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circulation Research. 1999;84:489-497.
42. Kamijo Y, Hora K, Kono K, et al. PPAR alpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrology. 2007;18:3089-4011.
43. Ruggenti P, Cattaneo D, Loriga G, et al. Ameliorating hypertension and insulin resistance ion subjects at increased cardiovascular risk. Hypertension. 2009;54:567-574.
44. Zhou Y, Berggren P, Grill V. A fatty acid-induced decrease in pyruvate hydrogenase activity is an important determination of beta-cell dysfunction in the obese diabetic db/db mouse. Diabetes. 1996;45:580-586.
45. Hotta K, Kuwajima M, Ono A, et al. Disordered expression of glyoclytic and gluconeogenic liver enzymes of juvenile visceral steatosis mice with systemic carnitine deficiency. Diabetes Research Clinical Practice. 1996;32:117-123.
46. Russo L, Sandoval R, Campos S, Molitoris B, Comper W, Brown D. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc of Nephrology. 2009;20:489-494.
47. Xu G, Liu A, Liu X. Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules. Nephrology. 2008;13:694-701.
48. Baumann M, von Eynatten M, Dan L, Kopuznetsova T, Heemann U, Staessen JA. Altered molecular weight forms of adiponectin in hypertension. J Clin Hypertens. 2009;11:11-16.
49. Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk factor of cardiovascular disease. Am J Cardiol. 2006;98:1603-1608.
50. Mitsnefes M, Kartal J, Khoury P, Daniels S. Adiponectin in children with chronic kidney disease: role of adiposity and kidney dysfunction. Clin J Am Soc Nephrol. 2007;2:46-50.
51. Ellington AA, Malik AR, Klee GG, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007;50:708-714.
52. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes. 2002;51:168-173.
53. Straznicky N, Lambert G, McGrane M, et al. Weight loss may reverse blunted sympathetic neural responsiveness to glucose ingestion in obese subjects with metabolic syndrome. Diabetes. 2009;58:1126-1132.
54. Thomopoulos C, Papadopoulos D, Papazachou O, et al. Free leptin is associated with masked hypertension in nonobese subjects. Hypertension. 2009;53:965-972.
55. Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. NEJM. 2009;360;44-52.
56. da Silva A, do Carmo J, Freeman J, Tallum L, Hall J. A functional melanocortin system may be required for CNS-mediated antidiabetic and cardiovascular actions of leptin. Diabetes. 2009;58:1749-1756.
57. Haynes W, Morgan D, Djalali A, Svitz W, Mark A. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension. 1999;33:542-547.
58. Greenstein AS, Khavandi K, Withers SB, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation. 2009;119:1661-1670.
59. Schling P, Mallow H, Trindl A, Löffler G. Evidence for a local renin angiotensin system in primary cultured human adipocytes, J Obes Relat Metab Disord. 1999;23:336-411.
60. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43(Part 2):358-363.
61. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors Proc Natl Acad Sci U S A. 2003 November 25;100(24):14211-14216.
62. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912-919.
63. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with Eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940-951.
64. Lefterova M, Mullican S, Tomaru T, Qatanani M, Schupp M, Lazar M. Endoplasmic reticulum stress regulated adipocyte resistin expression. Diabetes. 2009;58:1879-1886.
65. Wolf G, Chen S, Han D, Ziyadeh F. Leptin and renal disease. American J of Kidney Diseases. 2002;39:1-11.
66. Susztak K, Raff A, Schiffer M, Bottinger E. Glucose - induced reactive oxygen species causes apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55:225-233.
67. Chuang P, Yu Q, Fang W, Uribarri J, He J. Advanced glycation end products induce podocyte apoptosis by activation of the FOXO 4 transcription factor. Kid Int. 2007;72:965-976.
68. Pagtalunan M, Miller P, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type 2 diabetes. J Clin Invest. 1997;99:m342-m348
69. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin 2. Diabetes. 2003;52:1023-1030.
70. Nakagawa T, Kosugi T, Haneda M, Rivard C, Long D. Abnormal angiogenesis in diabetic nephropathy. Diabetes. 2009;58:1471-1478.
71. Hummel S, Pfluger M, Kriechauf S, Hummel M, Ziegler A. Predictors of overweight during childhood in offspring of parents with type 1 diabetes. Diabetes Care. 2009;32:921-925.
72. Kaufman F, Hirst K, Linder B, et al. Health Study Writing Group. Risk factors for Type 2 Diabetes in a sixth grade multiracial cohort. Diabetes Care. 2009;32:953-955.
73. Kong J, Qiao G, Zhang Z, Liu S, Li Y. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney International. 2008;74:1577-1581.
74. Worstman J, Matsuoka L, Chen T, Hollick M. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutrition. 2000;72:690-693.
75. Nagase M, Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res. 2009;32:649-657.
76. Dai C, Stolz D, St. Bastacky S, et al. The central role of integrin-linked kinase in podocyte biology: bridging the integrin and slit diagram signaling. J Am Soc Nephrol. 2006;17:2164-2175.
77. Ouchi N, Kihara S, Arita Y, et al. Novel modulator of endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.
78. Hajiwara S, Makita Y, Gu L, et al. Eicosopentanoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/TA mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant. 2006;21:605-615.
79. Shah KB, Duda MK, O'Shea KM, et al. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipids remodeling. Hypertension. 2009;54:605-611.
80. Miller ER 3rd, Juraschek SP, Appel LJ, et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. Am J Clin Nutr. 2009;89:1937-1945.